Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06933394 | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma | recruiting | Phase 2 | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | completed | Phase 1 | 45 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04474964 | Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.(FOR-WNT2) | recruiting | N/A | 30 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05772312 | Quality of Life of Patients With Bone Tumor of the Lower Limbs Treated With Salvage Surgery(Onco-QoL) | completed | — | 41 | Istituto Ortopedico RizzoliOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06323408 | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas(BZKF-AYA) | not yet recruiting | — | 72 | University Hospital RegensburgOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03496402 | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)(MICCHADO) | active not recruiting | N/A | 600 | Institut CurieOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06873672 | Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China | not yet recruiting | — | 360 | RenJi HospitalOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04315064 | Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma | completed | Early Phase 1 | 2 | The University of Texas Health Science Center, HoustonOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06243588 | Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma | recruiting | — | 400 | Istituto Ortopedico RizzoliOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05735977 | Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared(Nephrogreen) | completed | N/A | 12 | Birmingham Women's and Children's NHS Foundation TrustOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04246671 | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | completed | Phase 1 | 37 | Bavarian NordicINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06851221 | Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma | completed | N/A | 95 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06853080 | Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors | active not recruiting | Phase 2 | 6 | Taipei Medical UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06850506 | Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment | active not recruiting | — | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03778996 | SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma(HopES) | active not recruiting | Phase 2 | 31 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04897880 | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT(NORTH) | terminated | Phase 2 | 25 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 3 | Feb 24, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | recruiting | Phase 1 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT02030964 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan(DFMO) | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 3 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06000787 | MCT for the Harvard/UCSF ROBIN Center | recruiting | N/A | 47 | Brigham and Women's HospitalOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03083678 | Afatinib in Locally Advanced and Metastatic Chordoma | completed | Phase 2 | 43 | Leiden University Medical CenterOTHER | 3 | Feb 13, 2025 | clinicaltrials |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 85 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04903899 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma(LuDO-N) | recruiting | Phase 2 | 24 | Jakob StenmanOTHER | 5 | Feb 11, 2025 | clinicaltrials |
| NCT01586104 | Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases | completed | N/A | 20 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04023669 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | completed | Phase 1 | 21 | St. Jude Children's Research HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | recruiting | Phase 1 | 12 | Nanjing Children's HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06814353 | Intraoperatively Observed Site of Origin and Growth Pattern of Medulloblastoma(ISOP) | enrolling by invitation | — | 100 | Christian DorferOTHER | 3 | Feb 7, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT06794645 | Pembrolizumab and Pemetrexed for Progressive Chordoma | recruiting | Phase 2 | 21 | Saint John's Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06753318 | Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions | not yet recruiting | N/A | 716 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 18, 2025source: clinicaltrials